CELU · Celularity Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $5.28M | $5.74M | $11.43M | - | $9.30M | $12.11M | $14.68M | - | $3.79M |
| Cost of Revenue | - | $3.90M | $5.24M | $3.55M | - | $3.88M | $2.12M | $1.64M | - | - |
| Gross Profit | - | $1.38M | $494.0K | $7.87M | - | $5.41M | $9.99M | $13.04M | - | $184.0K |
| R&D | - | $4.60M | $3.35M | $3.73M | - | $3.92M | $3.80M | $5.84M | - | $5.18M |
| SG&A | - | $9.31M | $12.63M | $14.26M | - | $12.65M | $15.91M | $14.03M | - | $10.75M |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | - | $1.52M | $1.54M | $1.83M | - | $1.52M | $1.54M | $2.16M | - | $1.79M |
| Operating Income | - | ($12.90M) | ($15.86M) | ($10.49M) | - | ($11.53M) | ($10.18M) | ($7.38M) | - | ($99.26M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | $0 | $0 | $0 | - | $0 |
| Net Income | - | ($23.08M) | ($24.52M) | ($19.75M) | - | ($16.10M) | ($6.49M) | ($22.01M) | - | ($93.88M) |
| EPS - Basic | - | ($0.88) | ($1.02) | ($0.84) | - | ($0.73) | ($0.30) | ($1.03) | - | ($5.00) |
| EPS - Diluted | - | ($0.88) | ($1.02) | ($0.84) | - | ($0.73) | ($0.30) | ($1.03) | - | ($5.00) |
Balance Sheet
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.17M | $120.0K | $863.0K | $293.0K | $738.0K | $133.0K | $467.0K | $1.90M | $227.0K | $273.0K |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $571.0K | $2.56M | $4.41M | $6.20M | $5.41M | $3.96M | $2.92M | $3.70M | $5.75M | $4.93M |
| Accounts Payable | $26.42M | $24.59M | $24.40M | $23.31M | $23.30M | $15.40M | $13.73M | $12.98M | $14.14M | $12.93M |
| Current Assets | $12.32M | $10.60M | $17.26M | $22.08M | $20.56M | $14.50M | $17.73M | $22.86M | $19.79M | $16.50M |
| Total Assets | $107.33M | $114.24M | $120.28M | $128.88M | $132.68M | $128.84M | $135.49M | $143.82M | $143.89M | $157.19M |
| Current Liabilities | $80.76M | $65.31M | $69.23M | $58.69M | $53.68M | $76.17M | $67.90M | $66.04M | $67.30M | $84.63M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $145.39M | $134.33M | $145.78M | $134.38M | $123.84M | $111.56M | $107.68M | $112.57M | $102.93M | $126.94M |
| Stockholders' Equity | ($38.06M) | ($20.09M) | ($25.50M) | ($5.51M) | $8.84M | $17.28M | $27.81M | $31.25M | $40.96M | $30.25M |
| Retained Earnings | ($991.48M) | ($967.10M) | ($944.02M) | ($919.50M) | ($899.68M) | ($886.39M) | ($870.29M) | ($863.80M) | ($841.79M) | ($851.34M) |
Cash Flow
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($2.99M) | - | - | - | ($4.40M) | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | ($39.0K) | - | - |
| Financing Cash Flow | - | - | - | $2.32M | - | - | - | $6.23M | - | - |
| CapEx | - | - | - | - | - | - | - | $39.0K | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | ($4.44M) | - | - |
Ratios
| Metric | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | 26.1% | 8.6% | 68.9% | - | 58.2% | 82.5% | 88.8% | - | 4.9% |
| Operating margin | - | -244.1% | -276.6% | -91.8% | - | -124.0% | -84.0% | -50.2% | - | -2621.7% |
| EBITDA margin | - | -215.4% | -249.7% | -75.7% | - | -107.7% | -71.3% | -35.6% | - | -2574.4% |
| Net margin | - | -436.7% | -427.5% | -172.9% | - | -173.2% | -53.6% | -149.9% | - | -2479.6% |
| Free cash flow margin | - | - | - | - | - | - | - | -30.3% | - | - |
| FCF / Net income | - | - | - | - | - | - | - | 0.20 | - | - |
| R&D / Revenue | - | 87.0% | 58.4% | 32.6% | - | 42.1% | 31.4% | 39.8% | - | 136.9% |
| SG&A / Revenue | - | 176.1% | 220.3% | 124.8% | - | 136.1% | 131.3% | 95.6% | - | 283.9% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -20.2% | -20.4% | -15.3% | - | -12.5% | -4.8% | -15.3% | - | -59.7% |
| Return on equity | - | 114.8% | 96.2% | 358.8% | - | -93.2% | -23.3% | -70.5% | - | -310.4% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.15 | 0.16 | 0.25 | 0.38 | 0.38 | 0.19 | 0.26 | 0.35 | 0.29 | 0.19 |
| Quick ratio | 0.15 | 0.12 | 0.19 | 0.27 | 0.28 | 0.14 | 0.22 | 0.29 | 0.21 | 0.14 |
| Cash ratio | 0.08 | 0.00 | 0.01 | 0.00 | 0.01 | 0.00 | 0.01 | 0.03 | 0.00 | 0.00 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -2.82 | -5.69 | -4.72 | -23.41 | 15.01 | 7.46 | 4.87 | 4.60 | 3.51 | 5.20 |
| Liabilities / Assets | 1.35 | 1.18 | 1.21 | 1.04 | 0.93 | 0.87 | 0.79 | 0.78 | 0.72 | 0.81 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.05 | 0.05 | 0.09 | - | 0.07 | 0.09 | 0.10 | - | 0.02 |
| Inventory turnover | - | 1.52 | 1.19 | 0.57 | - | 0.98 | 0.73 | 0.44 | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | 240d | 307d | 636d | - | 373d | 501d | 824d | - | - |
| Days payable outstanding | - | 2299d | 1699d | 2394d | - | 1448d | 2360d | 2890d | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | 3.8x | 2.5x | 3.6x | - | 13.8x |
| P / S | - | 10.3x | 8.2x | 3.6x | - | 7.0x | 5.6x | 7.6x | - | 110.4x |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | -43.2% | -52.6% | -22.2% | - | 145.5% | 312.2% | 273.1% | - | -8.4% |
| Revenue CAGR (3y) | - | 8.5% | 21.5% | 62.6% | - | 40.5% | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | -74.5% | -95.1% | -39.6% | - | 2841.8% | 367.6% | 575.0% | - | - |
| Operating income growth (YoY) | - | -11.9% | -55.9% | -42.2% | - | 88.4% | 76.0% | 88.5% | - | -1658.0% |
| Net income growth (YoY) | - | -43.3% | -278.0% | 10.3% | - | 82.9% | 86.5% | 65.6% | - | - |
| EPS growth (YoY) | - | -20.5% | -240.0% | 18.4% | - | 85.4% | -11.1% | -151.2% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | 70.8% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | - | -78.4% | -42.9% | -76.5% | -79.9% | -79.4% | -81.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$26.55M totalDegenerative Disease$17.31M · 65.2%
Biobanking$5.43M · 20.5%
Cell Therapy$3.81M · 14.3%
Product / service
$26.55M totalProduct$13.18M · 49.6%
License Royalty And Other$7.94M · 29.9%
Service$5.43M · 20.5%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Celularity Inc against the 5 most active filers in the same SIC group.